Alkermes (ALKS)
In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Alkermes, with a price target of $63.00. The company’s shares closed last Friday at $52.89.
According to TipRanks.com, Matteis is a 5-star analyst with an average return of 17.8% and a 53.8% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, Neumora Therapeutics, Inc., and Lexeo Therapeutics, Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alkermes with a $54.85 average price target, representing a 2.8% upside. In a report issued on July 10, TipRanks – PerPlexity also upgraded the stock to Buy with a $60.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
